In this issue of Blood, Curran et al report clinical trial results evaluating a second-generation CD19-directed chimeric antigen receptor (CAR) T-cell therapy in pediatric and young adult (AYA) relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).1 Autologous CAR T-cell immunotherapies are revolutionizing the treatment of B-cell…
Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin JS Dyer, Michael J. Eckart, Lothar Müller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink
Key PointsVenetoclax (14 days) + azacitidine regimen was well tolerated in patients with treatment-naive HR MDS, with no unexpected safety findings.The reg
Key PointsDisruption of antioxidant selenoprotein synthesis exhibited significant defects in B lymphocyte development and HSC function.Cell context and lin
Key PointsB-cell maturation antigen–directed CAR-T therapy in patients with MM and CNS involvement is feasible without excess neurotoxicity.Data support CN
Key PointsDetection of mNPM1 MRD by NGS using DNA overcomes several limitations of RT-qPCR and is therefore an attractive alternative assay.The prognostic
Key PointsLenalidomide induces immunomodulating responses through the activation of dsRNA-sensing pathway.ADAR1 drives lenalidomide resistance in MM via th
Key Pointsα-Actinin-1 deficiency in MKs is associated with low platelet count and leads to impaired platelet function and thrombosis.α-Actinin-1 is critica
Key PointsOur study discovered new regulators of ruxolitinib response in Ph-like ALL, including c-MYC as a therapeutically targetable codependency.A progno
Key PointsWe developed of a high-throughput screening assay to identify small-molecule inhibitors of fibrin-mediated clot retraction.Screening 9710 compoun
Abstract. Measurable residual disease (MRD) is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia (ALL). In addition to its clear pr
